How to Know If Your Ulcerative Colitis Is Flaring

You cannot tell a flare from a bad week by how rough today feels. A flare in ulcerative colitis (UC) means active inflammation in the lining of the colon, and inflammation is something you measure rather than something you sense. What you can do at home is notice a change, and the changes that carry the most information are narrow: rectal bleeding that has returned or increased, stool frequency sitting above your own normal, new urgency, and stools that wake you at night, all persisting beyond two or three days.

That is the suspicion. The confirmation comes from a stool test, a blood test or a look inside. This guide is about how to build a suspicion you can act on, how to score yourself in two minutes with the same index your clinic uses, and how to avoid the two mistakes that catch nearly everyone: waiting because "it might be something I ate", and panicking because one bad day felt like the old days.

The short answer: measure the change, not the day

Ask yourself three questions, in this order. Has blood come back, or become more frequent than it has been? Is your stool frequency above your own usual number, not above somebody else's? Has that been true for more than two or three days in a row?

Two yeses out of three is enough to contact your IBD team. One yes plus urgency or a night-time stool is enough to start logging properly and to ask about a test. Three noes and one rough afternoon is probably not a flare, though it may still be worth writing down.

That framing matches how specialists grade UC. The American College of Gastroenterology's activity index for UC puts stools per day, blood in stools and urgency alongside haemoglobin, C-reactive protein (CRP), faecal calprotectin and endoscopic score, and describes mildly active disease as fewer than four stools daily with intermittent blood and mild, occasional urgency, moderate to severe disease as more than six stools with frequent blood and urgency that happens often, and fulminant disease as more than ten stools with continuous blood (Rubin 2025). Notice that three of the four things you can assess yourself are counts and frequencies, not adjectives.

What "flare" actually means to your IBD team

A flare means inflammation has become active again. That sounds obvious, but clinicians actually work with three separate layers of remission, and "am I flaring?" gets a different answer at each one.

The international STRIDE-II consensus sets clinical response and symptomatic remission as the immediate targets, normalisation of CRP and faecal calprotectin as an intermediate target, and endoscopic healing as the long-term target (Turner 2021). So you can be in symptomatic remission and out of biochemical remission at the same time, which is exactly the situation that confuses people most.

Research studies are even stricter. The PREdiCCt cohort, which followed 2,629 people with IBD in self-reported remission across 47 UK hospitals, counted a "patient-reported flare" separately from an "objective flare", and an objective flare required a clinical flare plus a CRP above 5 mg/L or faecal calprotectin above 250 micrograms per gram plus treatment escalation (Constantine-Cooke 2026). A rough week after a wedding does not meet that bar.

At the severe end, the language is much older and much simpler. Truelove and Witts, writing in 1955, defined severe disease as more than six bowel movements a day alongside fever, a fast heart rate, anaemia or a raised erythrocyte sedimentation rate (Truelove 1955). That definition is still the one used to decide who needs hospital admission today, and the ACG guideline reproduces it (Rubin 2025).

So when you ask "am I flaring", you are really asking one of these: are my symptoms back, are my markers up, or is my colon inflamed again. They usually move together. When they do not, that is information rather than a paradox.

Why you cannot answer this without knowing your baseline

The most common reason people get stuck is that they are comparing themselves against a description of remission they read somewhere, rather than against how they actually were three months ago.

A post in r/UlcerativeColitis titled "Is this a flare or just how it is?" captures it exactly. The person had been diagnosed 14 years earlier, had regular colonoscopies showing scarring but little or no inflammation, and described bathroom visits that were never short, abdominal spasms, and an achy, run-down feeling afterwards that sometimes came with blood or mucus and sometimes did not (r/UlcerativeColitis thread). Is that a flare or a baseline? Without a record, nobody can say.

The research says this is common, not unusual. In a study of 103 people with UC, across several definitions of mucosal healing, between 25% and 39% still reported increased stool frequency, compared with only 10% to 24% who reported rectal bleeding. The authors concluded that non-inflammatory changes such as long-term bowel damage may keep stool frequency up even after the lining has healed (Colombel 2017). In other words, a permanently higher stool count can be your new normal, and treating it as a flare signal will make you cry wolf every month.

The practical fix is unglamorous. Pick a quiet stretch when you feel as well as you get, and record for two weeks: stools per day, stools at night, whether there was blood, whether you had to hurry, and stool form. That is your baseline. Everything afterwards is measured against it. This is also why Clairop scores rectal bleeding and stool frequency against your own logged baseline rather than a fixed threshold: a bad week only means something relative to your normal.

The four signals that carry the most information

If you only track four things, track these.

1. Rectal bleeding. This is the strongest single symptom. In the same study of 103 people, the absence of rectal bleeding identified people with an inactive colon lining better than a normal stool frequency did, and better than the two combined, with sensitivity of 77% and specificity of 81% when mucosal healing was defined as a Mayo endoscopic subscore of 0 or 1 (Colombel 2017). The Mayo score grades bleeding from 0 for none, to 1 for streaks less than half the time, 2 for obvious blood most of the time, and 3 for blood passed alone (Schroeder 1987). Knowing which of those four you are on is more useful than "a bit of blood".

2. Stool frequency against your own baseline. Bleeding and frequency together make up PRO-2, the two-item patient-reported score derived from the Mayo score and developed for use in UC trials (Jairath 2015). Frequency is noisier than bleeding, for the reason above, but a sustained rise of two or three above your normal is meaningful.

3. Urgency. This is the signal most likely to be undercounted, because it is not in PRO-2 and it is easy to dismiss. It should not be. In the CONFIDE survey of 200 US and 556 European patients with moderate to severe UC and 200 US and 503 European clinicians, bowel urgency was among the three most common symptoms patients reported, and 45.0% of US and 37.0% of European patients said they had worn pads or protection at least weekly in the previous three months because of fear of incontinence. Clinicians ranked diarrhoea, blood and increased frequency as the top symptoms instead (Travis 2024). Urgency now has its own validated 11-point patient-reported scale (Dubinsky 2022). If urgency has changed, say so out loud at your appointment, because your clinician may not ask.

4. Night-time stools. Waking to open your bowels is one of the items in the Simple Clinical Colitis Activity Index, scored separately from daytime frequency (Walmsley 1998). It is a symptom that rarely comes from stress or from a food reaction alone, which is part of why it earns its own line.

Alongside these, record stool form on the Bristol scale, which was validated against whole-gut transit time in 66 volunteers and correlates with transit better than frequency does (Lewis 1997). "Type 6, five times" tells your team far more than "bad".

Score yourself: the SCCAI in two minutes

The Simple Clinical Colitis Activity Index was designed in 1998 to be quick and to need no laboratory tests, and the ACG guideline reproduces it in full (Walmsley 1998, Rubin 2025). You can complete it for yourself.

How to read your total. In a study of 66 people with UC who reported whether they considered themselves in remission, a SCCAI below about 2.5 corresponded to patient-defined remission, and a fall of more than 1.5 points corresponded to a clinically meaningful improvement (Higgins 2005). Those numbers give you two useful anchors: roughly where remission sits, and how big a change has to be before it is more than noise.

Can you trust your own scoring? Reasonably well. When 149 people with UC completed a patient version of the index on the same day their gastroenterologist scored them, the two correlated strongly, and they agreed on active disease versus remission in 87% of cases. In three quarters of cases the gap between patient and clinician scores was two points or less, and patients tended to report slightly more physical symptoms than clinicians recorded (Bennebroek Evertsz 2013).

The early signals people notice before the blood

Ask a colitis forum what tells them a flare is coming and you get a strikingly consistent list, none of it validated as an early-warning system. Treat this section as lived experience, useful for knowing what to log, not as evidence of anything.

In a thread asking "What are your first signs that you are going into a flare?", the most upvoted answer was exhaustion and a need for far more sleep, followed by stomach noises and wind. Others described a distinctive change in the smell of wind, mucus appearing days before any blood, mouth ulcers, joint pain arriving "like clockwork", skin flaring, acne, and feeling cold or generally unwell (r/UlcerativeColitis thread). A second thread asking about advance warning produced the same cluster, with several people adding that they started waking unusually early, and one noting that a raised calprotectin of 800 in April preceded symptoms that only started in September (r/UlcerativeColitis thread). A third described fatigue, mild abdominal discomfort, slightly different bowel movements and more joint pain after a year of remission (r/UlcerativeColitis thread).

Some of that has a plausible basis.

Fatigue. A systematic review found that among people with IBD in remission, the prevalence of fatigue ranged from 41% to 48%, and the authors noted the data were sparse and conflicting on whether fatigue severity tracks disease activity (van Langenberg 2010). Anaemia is a separate and very common contributor: the European consensus describes anaemia as the most common systemic complication of IBD, usually a combination of iron deficiency and anaemia of chronic disease, with a substantial effect on physical and cognitive function (Dignass 2015). So fatigue is worth reporting, but it is not specific.

Joints, skin and eyes. The first European consensus on extraintestinal manifestations states that most of them run in parallel with intestinal disease activity, with the exception of ankylosing spondylitis and uveitis. Type I peripheral arthritis, which is acute, affects a few large joints and comes on suddenly, is usually associated with active IBD, whereas type II, affecting many smaller joints, runs independently. Erythema nodosum, the tender red nodules that most often appear on the shins, is very often associated with active intestinal disease and usually settles when the bowel disease is controlled (Harbord 2016). That is a real reason a flaring joint or a new patch of shin nodules deserves a mention.

Mood. The direction of travel here is genuinely two-way. In a two-year prospective study of 405 people with IBD, those with quiescent disease and an abnormal anxiety score at baseline were about twice as likely to later need a steroid course or have a flare of disease activity (Gracie 2018). In 1,973 people in the Swiss IBD Cohort Study, depression was a strong predictor of later active disease (Jordi 2022). Low mood in the weeks before a flare may be part of the illness rather than a personal failing.

What nobody can tell you is whether your fatigue this week means anything. That is what a log is for: after two or three flares, you will know whether your own early signals repeat.

Why symptoms get it wrong in both directions

This is the part most articles skip, and it explains almost every confusing result.

You can feel fine and still be inflamed. In 149 people with UC in clinical remission by SCCAI who were having a surveillance colonoscopy, 45% had some endoscopic inflammation, and 13% had a Mayo endoscopic subscore above 1. Being in remission for less than six months, a higher white cell count and a higher CRP were independently associated with the more significant inflammation (Rosenberg 2013). Feeling well is not proof.

You can feel awful with a quiet colon. A meta-analysis of 27 studies and 3,169 people with IBD in remission found that 32.5% overall, and 28.7% of those with UC, met criteria for IBS-type symptoms. Where remission had been confirmed at endoscopy, the figure was 23.5% (Fairbrass 2020). Those symptoms are real; they are just not necessarily inflammation.

There is a catch, though, and it cuts the other way. In an earlier study, people with IBD thought to be in remission who met criteria for IBS had significantly higher faecal calprotectin than those who did not, which suggested that low-grade, occult inflammation explained a good share of their symptoms rather than a separate IBS (Keohane 2010). "It's probably just IBS" is a hypothesis, not a conclusion, and a test is cheap.

What a faecal calprotectin test can and cannot tell you

Calprotectin is a protein released by neutrophils, the white cells that flood into an inflamed bowel lining, and it survives the journey into stool, which is why a stool sample can stand in for looking inside.

How good is it? In that meta-analysis of symptomatic patients, faecal calprotectin had a pooled sensitivity of 0.88 and specificity of 0.73 for endoscopically active disease, and was more sensitive in UC than in Crohn's disease (Mosli 2015). Good at catching inflammation; less good at ruling other things out, because it rises in infection too.

Which number matters? The AGA guideline on biomarkers in UC suggests using faecal calprotectin below 150 micrograms per gram, normal faecal lactoferrin or normal CRP to rule out active inflammation in someone in symptomatic remission and avoid routine endoscopy, and suggests below 50 for people who have only recently achieved remission after a treatment change. With moderate to severe symptoms, it suggests a value above 150 to rule inflammation in and inform a treatment change without endoscopy. With mild symptoms, it suggests endoscopic assessment rather than an empirical treatment change, whether the biomarkers are high or normal (Singh 2023). The ACG activity index uses roughly 150 to 200 as the line between remission and active disease (Rubin 2025).

Does it predict a flare before you feel it? Reasonably often. In 41 people with quiescent UC followed for a year, those with a calprotectin above 150 micrograms per gram had a 14-fold higher risk of clinical relapse (Costa 2005). A meta-analysis of six prospective studies and 672 people with IBD found a pooled sensitivity of 78% and specificity of 73% for predicting relapse (Mao 2012). And in PREdiCCt, a baseline calprotectin at or above 250 was associated with a more than threefold higher risk of an objective flare over the following years (Constantine-Cooke 2026).

One value is weaker than two. A systematic review of studies that took repeated measurements found that people with two consecutive elevated results had a 53% to 83% probability of relapsing within the next two to three months, while people with repeatedly normal values had a 67% to 94% probability of staying in remission (Heida 2017).

Three further caveats are worth knowing before you read too much into a number. The AGA guideline notes that calprotectin assays are not interchangeable, so the same assay should be used for a given person over time; that there can be substantial within-stool and within-day variation, so confidence in any single measurement is limited; and that biomarkers may be less accurate at detecting inflammation in ulcerative proctitis or limited segmental disease (Singh 2023). If you have proctitis only, a normal calprotectin is less reassuring than it would be with extensive colitis.

Both directions of confusion show up constantly in colitis forums. One thread from someone with a result in the thousands drew replies pointing out that such a number does not predict a coming flare, it describes one that has already started (r/UlcerativeColitis thread). Another, from someone with a value of 476 and no symptoms, produced sensible advice to retest sooner rather than wait three months, and a note that the person's previous high value had coincided with a C. difficile infection while the colonoscopy was clean (r/UlcerativeColitis thread).

What each signal is actually telling you

Things that look exactly like a flare

Before you or your team conclude that UC is active, a short list of impostors needs ruling out. Several of them need completely different treatment.

Clostridioides difficile infection. This is the big one. The ACG guideline recommends stool testing to rule out C. difficile in anyone suspected of having UC, and again in anyone hospitalised with acute severe UC (Rubin 2025). In a US referral centre, the rate of C. difficile infection among people with IBD rose from 1.8% in 2004 to 4.6% in 2005, and infection was associated with worse outcomes (Issa 2007). It can present exactly like a relapse, and calprotectin rises with it.

Other gut infections, and cytomegalovirus. The ECCO guideline on infections in IBD covers the opportunistic infections that complicate immunosuppressive treatment, including CMV, which is specifically considered in colitis that is not responding to steroids (Kucharzik 2021). The AGA guideline makes the same point from the biomarker side: when biomarkers are elevated alongside symptoms, stool testing for C. difficile and other enteric pathogens matters, because these markers are not specific to IBD (Singh 2023).

NSAID painkillers. In a study where people with quiescent IBD took conventional NSAIDs such as naproxen, diclofenac or indomethacin for four weeks, 17% to 28% relapsed within nine days, with rising faecal calprotectin alongside (Takeuchi 2006). If you have taken ibuprofen for a back injury or a headache in the fortnight before symptoms started, say so, and ask your team what you should use instead rather than making that decision alone.

Missed maintenance treatment. In 99 people with quiescent UC on maintenance mesalamine, those refilling less than 80% of their prescription had more than five times the risk of relapse (Kane 2003). If treatment has been hard to take for any reason, cost, side effects or simply forgetting, that is a conversation to have with your team, not something to correct silently.

Stress. In a population-based study that surveyed 704 people with IBD every three months for a year, high perceived stress was the only factor independently associated with a later symptomatic flare, with roughly a 2.4-fold increase in odds. NSAIDs, antibiotics and non-gut infections were not associated in that particular study (Bernstein 2010). Flares in that study were defined by symptoms, so stress may act partly on how the gut feels as well as on inflammation.

A food reaction. Fermentable carbohydrates and fatty or spicy meals can produce a genuinely miserable 24 hours without touching inflammation. Our guide on whether food can trigger a UC flare walks through the evidence on that in detail, including why bleeding after a meal points to inflammation already being present rather than to the food.

Bleeding from lower down. Bright red blood on the paper only, particularly with pain on passing a hard stool, can come from the anal canal rather than the colon. That is not something to diagnose yourself; it is one of the things an examination sorts out quickly.

How long should you wait before calling?

There is no guideline that says "wait four days", so people invent their own rule, and the range is wide. In a thread asking exactly this question, from someone in remission for four years whose stool count had climbed from two or three a day to seven over five days, one reply said two or three days with no improvement, another said "a few days", and a third said one to two weeks, probably closer to two. The person emailed their doctor the next day and was sent for a calprotectin test and other bloods (r/UlcerativeColitis thread).

Two weeks is too long. Here is a more defensible rule, built from the thresholds above rather than from habit.

• Blood that is new, or more frequent than your usual pattern: contact your IBD team this week, whatever else is happening. Bleeding is the symptom that tracks inflammation most closely.
• No blood, but frequency up by two or more and urgency worse: give it 48 to 72 hours. If it has not started settling by day four, or is still climbing, make contact.
• Symptoms that started abruptly, with fever, vomiting, or after a household illness or travel: contact sooner, and expect a stool sample to be requested, because infection and flare look alike.
• A calprotectin result above your usual range while you feel well: do not ignore it and do not panic. Ask whether it should be repeated sooner than the default interval, since two consecutive elevated values carry far more weight than one (Heida 2017).
• More than six bloody stools a day with fever, a fast heart rate, faintness or severe abdominal pain: this is the Truelove and Witts definition of severe disease, and it needs same-day medical assessment (Truelove 1955, Rubin 2025).

Contacting early is not being a nuisance. In a randomised trial of 909 people with IBD in the Netherlands, a telemedicine system that had people log symptoms at home and flagged deteriorations to the clinic reduced outpatient visits over 12 months from a mean of 2.34 to 1.55 and reduced hospital admissions, without reducing reported quality of care (de Jong 2017). Structured early reporting reduced contact overall, rather than increasing it.

A worked example: two weeks, two people, the same complaint

Both of these people describe "my colitis is playing up". They need different answers.

Ama has left-sided colitis, has been in remission for two years, and normally opens her bowels twice a day with formed stools and no blood. Over ten days she notices her count rise to four, then five, with type 6 stools most mornings. She has started hurrying to the toilet, has woken once at 4am, and on three separate days has seen streaks of blood. She has had no fever and no travel. Her SCCAI works out at 1 for frequency, 1 for a night-time stool, 1 for hurry, 1 for trace blood and 1 for feeling slightly below par: a total of 5, above the remission band. She contacts her IBD nurse on day four of bleeding rather than waiting. A morning stool sample comes back with calprotectin at 620, a C. difficile test is negative, and her team steps up treatment and books a sigmoidoscopy.

Ruth has proctitis, has been in remission for 18 months, and normally opens her bowels three times a day, which has been her count since a bad flare five years ago. Over the same ten days she has three days of cramping, wind and looser stools, each following a takeaway, each settling within about 30 hours. There is no blood, no night-time waking, and no change in her baseline count on the other seven days. Her SCCAI total is 1. She brings the log to her routine review. Her calprotectin is 38. Her team suggests the symptoms fit an IBS-type overlap, which around a third of people with IBD in remission report (Fairbrass 2020), and refers her to a dietitian to try a short, structured low FODMAP trial with reintroduction rather than changing her colitis treatment.

Same opening sentence. Different pattern, different test result, different answer. The pattern is what a log gives you; the answer is what the test gives you.

Four months later Ruth's picture changes: her count creeps to six, she sees blood on four days, she wakes twice at night, and she had a stomach bug three weeks earlier. That is not the food pattern. She contacts her team that week.

What to write down so next time is easier

You do not need an app for this. You need six fields, filled in at the time rather than reconstructed at bedtime.

1. Stools during the day (a number, not "lots").
2. Stools at night (a number, including zero).
3. Blood (none, trace, obvious with stool, or blood alone, matching the Mayo wording).
4. Urgency (none, hurry, immediately, or an accident).
5. Stool form (Bristol type 1 to 7).
6. One line of context: sleep, stress, painkillers, illness in the house, missed doses, travel.

Add a monthly overall rating. The IBD-Control questionnaire, a 13-item patient-reported measure plus a 0 to 100 visual analogue scale, was developed from patient focus groups and validated against clinician assessment precisely so that disease control could be captured from the patient's point of view in a couple of minutes (Bodger 2014). PREdiCCt used it monthly to capture patient-reported flares across more than 2,600 people (Constantine-Cooke 2026).

If your team offers home calprotectin testing, it is reasonable to ask about. In a study of 51 people with IBD in clinical remission, results from a smartphone-based home test correlated well with the laboratory assay, agreement was 80% at a 250 cut-off, and 80% of participants said they would probably use it for future monitoring if the price were acceptable (Wei 2018). Availability varies enormously between health systems, so this is a question for your clinic rather than something to order blindly.

For more on choosing between paper, a spreadsheet and an app, and on why most tracking habits die within three weeks, see our guide to tracking ulcerative colitis. When you take a log in, the method page explains why a record is only worth as much as the number of days behind it.

Myths about knowing when you are flaring

Myth: "If there is no blood, it is not a flare." Bleeding is the most informative symptom, not a required one. In one study, across definitions of mucosal healing, 10% to 24% of people with a healed lining still reported bleeding and many with active disease reported none consistently (Colombel 2017). Absence of blood lowers the probability; it does not settle it.

Myth: "My bloods were normal last month, so I am fine." Up to a quarter of people with endoscopically active UC have a normal CRP (Rubin 2025), and pooled sensitivity of CRP for endoscopic activity is around 0.49 (Mosli 2015).

Myth: "A high calprotectin means a flare is coming." More often it means one has already begun, or that something else is inflaming the gut, including infection. It is a strong signal to be assessed, and the AGA suggests endoscopic assessment rather than an empirical treatment change when someone in symptomatic remission has an elevated biomarker (Singh 2023).

Myth: "A normal calprotectin means the symptoms are in my head." It means inflammation is less likely, which is genuinely useful. Symptoms may then come from IBS-type sensitivity, which affects roughly 29% of people with UC in remission (Fairbrass 2020), from bowel damage, or from low-grade inflammation a single sample missed (Keohane 2010). None of those is imaginary.

Myth: "Feeling well means healed." In 149 people in clinical remission, 45% had endoscopic inflammation (Rosenberg 2013). This is why STRIDE-II puts biomarker normalisation and endoscopic healing beyond symptom control as treatment targets (Turner 2021).

Myth: "Urgency is just something you live with." Patients rate it among their most disruptive symptoms while clinicians consistently rank it lower (Travis 2024), and it now has a validated scale of its own (Dubinsky 2022). If it has changed, it belongs in the first sentence you say at your appointment.

Myth: "I should wait until my next appointment." Waiting turns a treatable early flare into a harder one. Structured early reporting reduced outpatient visits and admissions in a randomised trial (de Jong 2017).

When to contact your IBD team, and when not to wait

Bring specifics, not adjectives. Stools per day compared with your normal, days with blood, night-time episodes, urgency, any missed treatment, any painkillers, any illness in the household, and the dates each thing started. If you want help phrasing the questions once you are in the room, our guide to questions to ask a gastroenterologist about colitis covers what to ask and what a good answer sounds like.

Contact your IBD team promptly if you have:

• New blood in your stool, or more blood than your usual pattern
• Stool frequency above your baseline for more than two or three days
• Stools that wake you at night
• New or worsening abdominal pain
• New urgency, or an accident
• Unintended weight loss, or eating much less because of symptoms
• Recent antibiotics, a stomach bug in the household, or regular NSAID use alongside worsening symptoms
• Unusual tiredness or breathlessness, which can point to anaemia (Dignass 2015)
• A raised calprotectin result, even if you feel well

Seek urgent, same-day medical help if you have:

• More than six bloody stools a day
• Fever, a racing heart, or feeling faint
• Signs of dehydration, such as passing very little urine, dizziness on standing, or being unable to keep fluids down
• Severe abdominal pain, or a swollen, tender abdomen

The ACG guideline describes acute severe UC using the Truelove and Witts criteria, more than six bowel movements a day plus a sign of systemic illness such as fever, tachycardia, anaemia or raised inflammatory markers, and treats it as an indication for hospital assessment rather than something to ride out at home (Rubin 2025, Truelove 1955).

Nothing here replaces your IBD team's advice, and none of it is a reason to start, stop or change any treatment on your own. What it can do is get you to the phone with a number instead of a feeling. For more on living with and monitoring colitis, browse our ulcerative colitis guides.